Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by Oak Ridge Investments LLC

Oak Ridge Investments LLC reduced its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 6.8% during the 4th quarter, HoldingsChannel reports. The fund owned 17,362 shares of the biopharmaceutical company’s stock after selling 1,260 shares during the period. Oak Ridge Investments LLC’s holdings in Ultragenyx Pharmaceutical were worth $730,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of RARE. Wealth Enhancement Advisory Services LLC raised its stake in Ultragenyx Pharmaceutical by 1.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company’s stock worth $928,000 after purchasing an additional 294 shares during the period. Motley Fool Asset Management LLC raised its position in shares of Ultragenyx Pharmaceutical by 0.3% in the 3rd quarter. Motley Fool Asset Management LLC now owns 141,649 shares of the biopharmaceutical company’s stock worth $8,005,000 after buying an additional 360 shares during the period. KBC Group NV boosted its holdings in Ultragenyx Pharmaceutical by 24.5% in the third quarter. KBC Group NV now owns 2,568 shares of the biopharmaceutical company’s stock valued at $143,000 after acquiring an additional 506 shares during the last quarter. M&T Bank Corp grew its position in Ultragenyx Pharmaceutical by 8.1% during the third quarter. M&T Bank Corp now owns 6,992 shares of the biopharmaceutical company’s stock valued at $388,000 after acquiring an additional 525 shares during the period. Finally, Amalgamated Bank increased its stake in Ultragenyx Pharmaceutical by 13.4% during the second quarter. Amalgamated Bank now owns 5,896 shares of the biopharmaceutical company’s stock worth $242,000 after acquiring an additional 696 shares during the last quarter. 97.67% of the stock is owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Trading Down 2.1 %

Ultragenyx Pharmaceutical stock opened at $40.00 on Monday. Ultragenyx Pharmaceutical Inc. has a 52 week low of $37.02 and a 52 week high of $60.37. The stock has a market cap of $3.69 billion, a P/E ratio of -6.18 and a beta of 0.58. The stock has a 50 day moving average of $45.10 and a 200-day moving average of $49.63.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.05. The firm had revenue of $139.49 million for the quarter, compared to the consensus estimate of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The firm’s revenue was up 42.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($2.23) EPS. As a group, equities analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on RARE shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $116.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Piper Sandler boosted their price objective on shares of Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Monday, January 13th. JPMorgan Chase & Co. cut their target price on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a research note on Thursday, November 21st. Canaccord Genuity Group reaffirmed a “buy” rating and set a $121.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, November 12th. Finally, TD Cowen raised their price objective on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a research report on Monday, October 21st. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat, Ultragenyx Pharmaceutical presently has an average rating of “Moderate Buy” and a consensus price target of $92.29.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 8,273 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $50.00, for a total transaction of $413,650.00. Following the sale, the chief executive officer now owns 2,195,712 shares in the company, valued at $109,785,600. This represents a 0.38 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.